-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Immune checkpoint inhibitors (ICIs), including anti-programmed death-1 (anti-PD-1), anti-programmed death ligand-1 (anti-PD-L1), and anti-cytotoxic T-cell lymphocyte-associated antigen-4 ( Anti-CTLA-4) monoclonal antibody, represents a breakthrough in cancer therapy and has shown great promise in the treatment of non-small cell lung cancer ( NSCLC ) and head and neck squamous cell carcinoma (HNSCC) in addition to melanoma benef.
Immune checkpoint inhibitors (ICIs), including anti-programmed death-1 (anti-PD-1), anti-programmed death ligand-1 (anti-PD-L1), and anti-cytotoxic T-cell lymphocyte-associated antigen-4 ( Anti-CTLA-4) monoclonal antibody, represents a breakthrough in cancer therapy and has shown great promise in the treatment of non-small cell lung cancer ( NSCLC ) and head and neck squamous cell carcinoma (HNSCC) in addition to melanoma benef.
Various types of cutaneous irAEs have been described in previous reports, including maculopapular rash (MPE), pruritus, and ecze.
However, cutaneous irAEs have primarily been studied in clinical trials, Caucasians, or melanoma patients using general terms, but have not been systematically delineated in dermatological ter.
In this retrospective cohort study, 468 cancer patients who received immunotherapy at a tertiary referral center in Taiwan were finally included and sought to determine the true incidence of skin immune-related adverse events and their association with surviv.
In this retrospective cohort study, 468 cancer patients who received immunotherapy at a tertiary referral center in Taiwan were finally included and sought to determine the true incidence of skin immune-related adverse events and their association with surviv.
Of these, 128 patients (24%) had cutaneous immune-related adverse events, with maculopapular rash (16%) and pruritus (11%) being the most common in the monotherapy gro.
Subgroup analysis using chi-square test and Bonferroni test application showed that concurrent use of molecularly targeted therapy was associated with a higher incidence of immunotherapy (58%, P <.
Kaplan-Meier plot and log-rank test showed that patients with any type of immune-related skin adverse event had longer survival time than patients without immune-related skin adverse event (mean 600±66 days, 295±14 days, P <0001) (Figure
In conclusion, any type of skin immune-related adverse event was associated with longer overall survival in cancer patients receiving immunothera.
Original source:
Cho YT, Lin YT, Yang CW, Chu .
0001-->
Author: LILYMED Source: MedSci Original
Copyright statement:All texts, pictures and audio and video materials marked "Source: MedSci" or "Original Source: MedSci" on this website are copyrighted by MedSci and may not be reproduced by any media, website or individual without authorizati.
, the authorized reprint must indicate "Source: Mace Medica.
All reprinted articles on this website are for the purpose of transmitting more information, and clearly indicate the source and auth.
Media or individuals who do not wish to be reprinted can contact us, and we will delete them immediate.
At the same time, the reprinted content does not represent the position of this si.
leave a message here
0001-->, the authorized reprint must indicate "Source: Mace Medica.
All reprinted articles on this website are for the purpose of transmitting more information, and clearly indicate the source and auth.
Media or individuals who do not wish to be reprinted can contact us, and we will delete them immediate.
At the same time, the reprinted content does not represent the position of this si.
leave a message here
Subgroup analysis using chi-square test and Bonferroni test application showed that concurrent use of molecularly targeted therapy was associated with a higher incidence of immunotherapy (58%, P <.
0001>
Kaplan-Meier plot and log-rank test showed that patients with any type of immune-related skin adverse event had longer survival time than patients without immune-related skin adverse event (mean 600±66 days, 295±14 days, P <0001) (Figure
In conclusion, any type of skin immune-related adverse event was associated with longer overall survival in cancer patients receiving immunothera.
Prompt diagnosis and appropriate treatment are importa.
Original source:
Cho YT, Lin YT, Yang CW, Chu .
Cutaneous immune-related adverse events among Taiwanese cancer patients receiving immune checkpoint inhibitors link to a survival benef.
Sci Re.
2022;12(1):702 Published 2022 Apr 2 doi :11038/s41598-022-11128-5
0001>
Kaplan-Meier plot and log-rank test showed that patients with any type of immune-related skin adverse event had longer survival time than patients without immune-related skin adverse event (mean 600±66 days, 295±14 days, P <0001) (Figure
In conclusion, any type of skin immune-related adverse event was associated with longer overall survival in cancer patients receiving immunothera.
Prompt diagnosis and appropriate treatment are importa.
Original source:
Cho YT, Lin YT, Yang CW, Chu .
Cutaneous immune-related adverse events among Taiwanese cancer patients receiving immune checkpoint inhibitors link to a survival benef.
Sci Re.
2022;12(1):702 Published 2022 Apr 2 doi :11038/s41598-022-11128-5
Kaplan-Meier plot and log-rank test showed that patients with any type of immune-related skin adverse event had longer survival time than patients without immune-related skin adverse event (mean 600±66 days, 295±14 days, P <0001) (Figure
In conclusion, any type of skin immune-related adverse event was associated with longer overall survival in cancer patients receiving immunothera.
Prompt diagnosis and appropriate treatment are importa.
Prompt diagnosis and appropriate treatment are importa.
diagnosis
Original source:
Original source:Cho YT, Lin YT, Yang CW, Chu .
Cutaneous immune-related adverse events among Taiwanese cancer patients receiving immune checkpoint inhibitors link to a survival benef.
Sci Re.
2022;12(1):702 Published 2022 Apr 2 doi :11038/s41598-022-11128-5
Cutaneous immune-related adverse events among Taiwanese cancer patients receiving immune checkpoint inhibitors link to a survival benef.
Sci Re.
2022;12(1):702 Published 2022 Apr 2 doi :11038/s41598-022-11128-5 Sci Rep leave a message here
